FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885486546> ?p ?o ?g. }

• W2885486546 abstract "Purpose The purpose of this study was to examine use of granulocyte colony-stimulating factors (G-CSF) in relation to risk of myelodysplastic syndrome and acute myeloid leukemia (MDS/AML) in a population-based cohort of elderly patients with non-Hodgkin lymphoma (NHL). Methods We conducted a retrospective cohort study of adults ages 66 years and older diagnosed with first primary NHL between 2001 and 2011 using the Surveillance Epidemiology and End Results (SEER)-Medicare linked database. Patients were included if they were alive and without documented secondary primary cancer at three months post-diagnosis. Using a validated algorithm with Medicare claims and SEER records, we identified MDS/AML cases, primary NHL treatment received (i.e., chemo-immunotherapy and radiation) and type and number of doses of G-CSF received (i.e., filgrastim and/or pegfilgrastim). We determined the risk of developing MDS/AML at 12 months or longer after NHL diagnosis. We estimated adjusted hazard ratios (HR) and 95% confidence intervals (CI) for MDS/AML risk associated with G-CSF use in cause-specific Cox proportional hazards models, stratified by treatment to account for confounding by indication. Results A total of 18,245 patients were included with a mean age of 76 years and median follow up of 3.5 years. Most patients were diagnosed with diffuse large B-cell lymphoma (34%) and follicular lymphoma (22%). Fifty-six percent of all patients received chemo-immunotherapy, among whom most received rituximab-based chemotherapy (74%) or monotherapy (18%). G-CSF was most commonly used among those who received rituximab plus chemotherapy (77%). Subsequent MDS/AML was observed in 666 (3.7%) patients. Overall, we found a modest increased risk of MDS/AML with any use of G-CSF (HR=1.28, 95% CI 1.01-1.62); although, a linear trend was observed with increasing number of G-CSF doses (P Conclusions In this study of elderly NHL patients, we observed a higher MDS/AML risk among those receiving chemo-immunotherapy and G-CSF that was specific to higher number of filgrastim doses but not pegfilgrastim. The benefits of preventing complications from therapy-related neutropenia in patients receiving highly myeloablative treatments likely outweigh the risk of this rare but serious second primary cancer. Understanding differential risk by type of agent warrants further study with the increasing use of G-CSF and FDA-approved biosimilar products (filgrastim-sndz) newly available. Citation Format: Kellyn M. Moran, Zhaoju Wu, Sruthi Adimadhyam, Todd A. Lee, Brian C. Chiu, Gregory S. Calip. Myelodysplastic syndrome and acute myeloid leukemia following use of chemo-immunotherapy and granulocyte colony-stimulating factors among elderly non-Hodgkin lymphoma patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4225." @default.
• W2885486546 created "2018-08-22" @default.
• W2885486546 creator A5006255544 @default.
• W2885486546 creator A5026537297 @default.
• W2885486546 creator A5039490716 @default.
• W2885486546 creator A5046614364 @default.
• W2885486546 creator A5065181780 @default.
• W2885486546 creator A5069044966 @default.
• W2885486546 date "2018-07-01" @default.
• W2885486546 modified "2023-09-25" @default.
• W2885486546 title "Abstract 4225: Myelodysplastic syndrome and acute myeloid leukemia following use of chemo-immunotherapy and granulocyte colony-stimulating factors among elderly non-Hodgkin lymphoma patients" @default.
• W2885486546 doi "https://doi.org/10.1158/1538-7445.am2018-4225" @default.
• W2885486546 hasPublicationYear "2018" @default.
• W2885486546 type Work @default.
• W2885486546 sameAs 2885486546 @default.
• W2885486546 citedByCount "0" @default.
• W2885486546 crossrefType "proceedings-article" @default.
• W2885486546 hasAuthorship W2885486546A5006255544 @default.
• W2885486546 hasAuthorship W2885486546A5026537297 @default.
• W2885486546 hasAuthorship W2885486546A5039490716 @default.
• W2885486546 hasAuthorship W2885486546A5046614364 @default.
• W2885486546 hasAuthorship W2885486546A5065181780 @default.
• W2885486546 hasAuthorship W2885486546A5069044966 @default.
• W2885486546 hasConcept C121608353 @default.
• W2885486546 hasConcept C126322002 @default.
• W2885486546 hasConcept C143998085 @default.
• W2885486546 hasConcept C167135981 @default.
• W2885486546 hasConcept C207103383 @default.
• W2885486546 hasConcept C2776694085 @default.
• W2885486546 hasConcept C2777058707 @default.
• W2885486546 hasConcept C2777767877 @default.
• W2885486546 hasConcept C2778527826 @default.
• W2885486546 hasConcept C2778559949 @default.
• W2885486546 hasConcept C2778658803 @default.
• W2885486546 hasConcept C2778729363 @default.
• W2885486546 hasConcept C2779171977 @default.
• W2885486546 hasConcept C2779338263 @default.
• W2885486546 hasConcept C2780007613 @default.
• W2885486546 hasConcept C2780653079 @default.
• W2885486546 hasConcept C2780817109 @default.
• W2885486546 hasConcept C2781214270 @default.
• W2885486546 hasConcept C2908647359 @default.
• W2885486546 hasConcept C44249647 @default.
• W2885486546 hasConcept C50382708 @default.
• W2885486546 hasConcept C71924100 @default.
• W2885486546 hasConcept C99454951 @default.
• W2885486546 hasConceptScore W2885486546C121608353 @default.
• W2885486546 hasConceptScore W2885486546C126322002 @default.
• W2885486546 hasConceptScore W2885486546C143998085 @default.
• W2885486546 hasConceptScore W2885486546C167135981 @default.
• W2885486546 hasConceptScore W2885486546C207103383 @default.
• W2885486546 hasConceptScore W2885486546C2776694085 @default.
• W2885486546 hasConceptScore W2885486546C2777058707 @default.
• W2885486546 hasConceptScore W2885486546C2777767877 @default.
• W2885486546 hasConceptScore W2885486546C2778527826 @default.
• W2885486546 hasConceptScore W2885486546C2778559949 @default.
• W2885486546 hasConceptScore W2885486546C2778658803 @default.
• W2885486546 hasConceptScore W2885486546C2778729363 @default.
• W2885486546 hasConceptScore W2885486546C2779171977 @default.
• W2885486546 hasConceptScore W2885486546C2779338263 @default.
• W2885486546 hasConceptScore W2885486546C2780007613 @default.
• W2885486546 hasConceptScore W2885486546C2780653079 @default.
• W2885486546 hasConceptScore W2885486546C2780817109 @default.
• W2885486546 hasConceptScore W2885486546C2781214270 @default.
• W2885486546 hasConceptScore W2885486546C2908647359 @default.
• W2885486546 hasConceptScore W2885486546C44249647 @default.
• W2885486546 hasConceptScore W2885486546C50382708 @default.
• W2885486546 hasConceptScore W2885486546C71924100 @default.
• W2885486546 hasConceptScore W2885486546C99454951 @default.
• W2885486546 hasLocation W28854865461 @default.
• W2885486546 hasOpenAccess W2885486546 @default.
• W2885486546 hasPrimaryLocation W28854865461 @default.
• W2885486546 hasRelatedWork W1456239636 @default.
• W2885486546 hasRelatedWork W1817151680 @default.
• W2885486546 hasRelatedWork W1997539222 @default.
• W2885486546 hasRelatedWork W2002520574 @default.
• W2885486546 hasRelatedWork W2012238656 @default.
• W2885486546 hasRelatedWork W2108492034 @default.
• W2885486546 hasRelatedWork W2110119190 @default.
• W2885486546 hasRelatedWork W2522984597 @default.
• W2885486546 hasRelatedWork W2603276267 @default.
• W2885486546 hasRelatedWork W2885486546 @default.
• W2885486546 isParatext "false" @default.
• W2885486546 isRetracted "false" @default.
• W2885486546 magId "2885486546" @default.
• W2885486546 workType "article" @default.